China-based Unicet Biotech has completed a Series A equity financing round of nearly RMB 200 million (USD 30 million). Investors include Lapam Capital, ZGC Group, and others. The proceeds will be directed toward clinical development of the company's lead asset, preclinical proof‑of‑concept studies, and further refinement of its proprietary γδ T‑cell engineering platform. The company's technology is built on over two decades of research into γδ T‑cell biology and the BTN family of regulators, which act as molecular switches controlling T‑cell activation.

The lead candidate, QH104A, is a universal allogeneic CAR‑γδ T‑cell therapy targeting B7H3 for malignant gliomas. In 2025, it became the first CAR‑γδ T‑cell candidate to receive both Innovative New Drug (IND) clearance and Orphan Drug Designation (ODD) in the US. The therapy employs a dual‑targeting mechanism combining γδ TCR‑dependent recognition of tumour metabolic stress signals with CAR‑mediated specificity for B7H3. Additional pipeline assets include CD19‑targeted and CD19×BCMA dual‑targeted CAR‑γδ T‑cell therapies for haematological malignancies.

According to PharmCube's MedAlpha® database, Unicet has reported a total of USD 45 million raised in four financing events. Click here to request a free trial for MedAlpha®.